- Home
- PRTA vs SXC Comparison
PRTA vs SXC Comparison
Compare PRTA & SXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRTA
- SXC
- Stock Information
- Founded
- PRTA 2012
- SXC 1960
- Country
- PRTA Ireland
- SXC United States
- Employees
- PRTA N/A
- SXC N/A
- Industry
- PRTA Biotechnology: Pharmaceutical Preparations
- SXC Steel/Iron Ore
- Sector
- PRTA Health Care
- SXC Industrials
- Exchange
- PRTA Nasdaq
- SXC Nasdaq
- Market Cap
- PRTA 809.8M
- SXC 710.2M
- IPO Year
- PRTA N/A
- SXC N/A
- Fundamental
- Price
- PRTA $9.20
- SXC $9.35
- Analyst Decision
- PRTA Buy
- SXC Strong Buy
- Analyst Count
- PRTA 9
- SXC 1
- Target Price
- PRTA $54.57
- SXC $13.00
- AVG Volume (30 Days)
- PRTA 572.3K
- SXC 1.0M
- Earning Date
- PRTA 05-07-2025
- SXC 04-30-2025
- Dividend Yield
- PRTA N/A
- SXC 5.14%
- EPS Growth
- PRTA N/A
- SXC 64.98
- EPS
- PRTA N/A
- SXC 1.12
- Revenue
- PRTA $135,157,000.00
- SXC $1,935,400,000.00
- Revenue This Year
- PRTA N/A
- SXC N/A
- Revenue Next Year
- PRTA $131.71
- SXC $3.70
- P/E Ratio
- PRTA N/A
- SXC $8.35
- Revenue Growth
- PRTA 47.92
- SXC N/A
- 52 Week Low
- PRTA $9.10
- SXC $7.47
- 52 Week High
- PRTA $25.42
- SXC $12.82
- Technical
- Relative Strength Index (RSI)
- PRTA 26.58
- SXC 56.40
- Support Level
- PRTA $9.30
- SXC $8.90
- Resistance Level
- PRTA $10.45
- SXC $9.12
- Average True Range (ATR)
- PRTA 0.81
- SXC 0.36
- MACD
- PRTA -0.15
- SXC 0.07
- Stochastic Oscillator
- PRTA 2.77
- SXC 96.77
About PRTA Prothena Corporation plc
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
About SXC SunCoke Energy Inc.
SunCoke Energy Inc operates as an independent producer of coke in the Americas. Its coke is primarily used as a principal raw material in the blast furnace steelmaking process as well as in the foundry production of casted iron. The company operates through three segments: Domestic Coke, Brazil Coke, and Logistics. It offers metallurgical and thermal coal. The company also provides handling and/or mixing services to steel, coke, electric utility, coal producing, and other manufacturing-based customers. The majority of revenue is derived from the Domestic Coke segment.